CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$53.74 USD
-0.32 (-0.59%)
Updated May 31, 2024 04:00 PM ET
After-Market: $53.98 +0.24 (0.45%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
CRISPR Therapeutics AG [CRSP]
Reports for Purchase
Showing records 201 - 212 ( 212 total )
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Gene-Editing Is Clearly Not A Fiction. Reiterate Buy. PT Raised To $100.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
KOL Call with Dr. Sandeep Soni on December 4, 2019 at 1pm ET
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
3Q19 - Full Steam Ahead. Data Possible at ASH.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
CRISPR Engineering Could Provide Immune-Evasive Cell Therapy for Diabetes
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
2Q19 Update - Raising Our PT to $65/ Share As CTX110 Enters The Clinic
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Momentum Builds With Two IND Approvals. Initiating at Buy. $50 PT.
Provider: Roth Capital Partners, Inc.
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Momentum Builds With Two IND Approvals. Initiating at Buy. $50 PT.
Provider: Roth Capital Partners, Inc.